Liu Xiaoming, Zou Yao, Chen Xiaojuan, Wang Shuchun, Guo Ye, Yang Wenyu, Zhang Li, Chen Yumei, Zhang Yingchi, Zhu Xiaofan
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Division of Pediatric Blood Diseases Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Leuk Lymphoma. 2020 Dec;61(14):3460-3467. doi: 10.1080/10428194.2020.1805739. Epub 2020 Aug 11.
To evaluate the optimal time to monitor minimal residual disease (MRD) for pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL). Children newly diagnosed with T-ALL were treated per the CCLG-ALL2008 protocol in our hospital. MRD was monitored at days 15, 33 and 90, and the patients were stratified as low-, intermediate- or high-risk according to MRD at days 33 and 90. The 5-year event-free survival (EFS) and overall survival (OS) rates for all patients were 60.1 ± 5.6% and 63.1 ± 5.6%, respectively. The median follow-up time was 54 (0.3-120) months. Univariate analysis showed that the 5-year EFS rate correlated with MRD at days 33 and 90 ( < .01). Multivariate analysis demonstrated that only MRD at day 90 and involvement of the central nervous system (CNS) were independent prognostic factors. MRD at day 90 likely provides better prognostic value for pediatric T-ALL patients. ClinicalTrials.gov identifier: NCT00707083.
评估监测T细胞急性淋巴细胞白血病（T-ALL）患儿微小残留病（MRD）的最佳时间。我院新诊断的T-ALL患儿按照CCLG-ALL2008方案进行治疗。在第15、33和90天监测MRD，并根据第33天和90天的MRD将患者分为低危、中危或高危。所有患者的5年无事件生存率（EFS）和总生存率（OS）分别为60.1±5.6%和63.1±5.6%。中位随访时间为54（0.3 - 120）个月。单因素分析显示，5年EFS率与第33天和90天的MRD相关（P<0.01）。多因素分析表明，只有第90天的MRD和中枢神经系统（CNS）受累是独立的预后因素。第90天的MRD可能为小儿T-ALL患者提供更好的预后价值。ClinicalTrials.gov标识符：NCT00707083。
